嗜酸性粒细胞性食管炎与胃肠道癌症发病风险的人群队列研究
基于丹麦全国健康登记数据,纳入1997至2024年诊断的9115例嗜酸性粒细胞性食管炎(EoE)患者,分析其胃肠道癌症标准化发病比(SIR)。诊断后1年内总体SIR为2.83(95%CI 2.10-3.74),1年后总体SIR降至1.03(0.85-1.23),但食管癌(2.40[1.42-3.79])和肝细胞癌(2.05[0.98-3.77])风险仍升高;多数1年后发生的食管癌患者有巴雷特食管(BE)病史,提示EoE与食管癌的关联可能主要通过BE介导。
要点
- EoE诊断后1年内胃肠道癌症总体风险显著升高,SIR为2.83。
- 诊断1年后总体癌症风险不再升高,但食管癌和肝细胞癌风险仍偏高。
- EoE患者1年后发生的食管癌多伴有BE病史,BE可能是主要中介因素。
核心结论
- EoE诊断1年后食管癌和肝细胞癌发病率仍升高。
- 多数1年后发生的食管癌患者有BE病史,EoE与食管癌的关联可能主要通过BE介导。
研究设计与样本
- 基于丹麦全国健康登记的人群队列研究,纳入1997至2024年诊断的EoE患者9115例。
- 采用验证算法识别EoE,计算胃肠道癌症总体及部位特异性标准化发病比(SIR),并与一般人群比较。
- 分析按EoE诊断后<1年和≥1年分层,并分析合并BE的EoE患者食管癌发病率。
主要发现
- 9115例EoE患者中170例发生胃肠道癌症。
- 诊断后1年内总体SIR为2.83(95%CI 2.10-3.74)。
- 诊断1年后总体SIR为1.03(95%CI 0.85-1.23)。
- 诊断1年后食管癌SIR为2.40(95%CI 1.42-3.79),肝细胞癌SIR为2.05(95%CI 0.98-3.77)。
- EoE合并BE患者食管癌SIR为5.44(95%CI 2.90-9.31),单纯BE患者为4.84(95%CI 4.36-5.37)。
临床怎么用
- EoE诊断后应关注长期食管癌和肝细胞癌风险,尤其合并BE者。
- 对EoE合并BE患者,建议按BE相关指南进行食管癌监测。
局限性
- 单纯EoE患者食管癌SIR因癌症病例数少无法报告。
- 研究为观察性设计,不能完全排除残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence concerning gastrointestinal cancer risk after eosinophilic oesophagitis (EoE) diagnosis is limited. AIMS: To examine the association between EoE and incident gastrointestinal cancer in a population-based cohort. METHODS: Using nationwide Danish health registries, we identified all patients diagnosed with EoE between 1997 and 2024, using a validated algorithm. We computed standardised incidence ratios (SIRs) for gastrointestinal cancers overall and site-specific cancers compared with the general population. To distinguish short-term diagnostic activity from longer-term risk, we stratified analyses by < 1 and ≥ 1 year after EoE diagnosis. Secondary analyses examined oesophageal cancer incidence among EoE patients with coexisting Barrett's oesophagus (BE). RESULTS: Among 9115 EoE patients, 170 developed gastrointestinal cancers. During the first year after EoE diagnosis, the SIR was 2.83 (95% confidence interval: 2.10-3.74). Beyond 1 year, the overall SIR attenuated (1.03 [0.85-1.23]) but remained elevated for oesophageal cancer (2.40 [1.42-3.79]) and hepatocellular carcinoma (2.05 [0.98-3.77]). Among patients who developed oesophageal cancer ≥ 1 year after EoE diagnosis (n = 18), most had prior BE. The SIR for oesophageal cancer was 5.44 (2.90-9.31) among patients with both EoE and BE and 4.84 (4.36-5.37) among patients with BE alone. SIR for patients with EoE alone could not be reported due to the low number of cancer cases. CONCLUSIONS: One year after EoE diagnosis, oesophageal cancer and hepatocellular carcinoma rates remained elevated. Most oesophageal cancers occurred in patients with prior BE, suggesting that the association between EoE and oesophageal cancer may be mediated largely through BE.
引用
- Kurt G, Farkas DK, Dellon ES, et al. Eosinophilic Oesophagitis and Incidence of Gastrointestinal Cancer: A Population-Based Cohort Study. Aliment Pharmacol Ther. 2026. PMID: 42902446. doi:10.1111/apt.71061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。